Empowering Mass Spec for Biotech and Beyond
Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control.
Total raised
$8.7M
Last stage
Series A
Investors
Mason Chilmonczyk
Mason is the co-founder and CEO of Andson Biotech, an academic spinout based on Mason's research at the Georgia Institute of Technology. At Andson, Mason is driving the company's mission to develop novel methodologies for advanced biomanufacturing discovery and monitoring. Mason is formally trained as a mechanical engineer with a BS from the University of South Florida ('14) and an MS and PhD from Georgia Tech ('17, '20).
Mason Chilmonczyk
Mason is the co-founder and CEO of Andson Biotech, an academic spinout based on Mason's research at the Georgia Institute of Technology. At Andson, Mason is driving the company's mission to develop novel methodologies for advanced biomanufacturing discovery and monitoring. Mason is formally trained as a mechanical engineer with a BS from the University of South Florida ('14) and an MS and PhD from Georgia Tech ('17, '20).
LinkedInAndrei Fedorov
Professor who co-founded Andson Biotech with expertise in biotools for mass spectrometry sample prep and analytics.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.
